Crowdonomics
All companies
Eyedaptic logo

Eyedaptic

Operating

Eyedaptic, Inc.

Healthcare · Laguna Hills, CA · Founded 2016

Augmented Reality Glasses for Vision Loss

Post-money valuation ⓘ
$12.7M
As of Oct 2021 · from Reg CF Offering (2021) · pre-money + amount raised, not a traded price
Total raised
$2,137,755
Crowd $665K · Private $1.5M · 5 rounds since 2017
Latest share price
$0.80
Reg CF · Common Stock · Jan 2021 offering price

Financials

FY2018–FY2023 · from SEC filings · hover any figure for its source
$0
−$796K
2018
$6K
−$796K
2019
$62K
−$654K
2020
$205K
−$717K
2021
$212K
−$677K
2022
$458K
−$687K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018 reviewed*
FY2019 reviewed*
FY2020
FY2021
FY2022 unaudited
FY2023 unaudited
Income statement
Revenue
$0
$5,580
$62,313
$204,568
$212,230
$458,408
Cost of goods sold
$0
$4,522
$38,398
$113,550
$88,219
$203,358
Gross margin
—
19%
38%
44%
58%
56%
Net income
-$795,652
-$795,652
-$653,856
-$716,558
-$676,833
-$686,966
Taxes paid
$0
$0
$0
$0
$800
$800
Balance sheet
Cash
$450,608
$450,608
$363,254
$399,021
$508,134
$713,355
Accounts receivable
$0
$0
$0
$0
$0
$0
Total assets
$450,608
$450,608
$379,118
$465,768
$671,604
$883,555
Short-term debt
$23,510
$23,510
$234,368
$1,278,001
$1,614,132
$1,721,468
Long-term debt
$625,000
$625,000
$971,319
$147,000
$675,000
$1,255,000
Total liabilities
$648,510
$648,510
$853,457
$1,425,001
$2,289,132
$2,976,468
Other
Headcount
—
3
3
3
4
3

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$12.0M
pre-money
Reg CF · Common · Jan 2021

Blue bars are the pre-money valuation the company stated for a priced round.

Cap table

Share counts as of Dec 31, 2023
ClassOutstandingVotes / shareShare of totalLast price
common stock3,779,865—100.0%$0.80Jan 2021

Shares outstanding over timein today's share terms

3.8M1.9M0
Dec 2018Dec 2023
common stockRound opened

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $665.3K / $1.1MInvestors 653Post-money $12.7M
Raised $50KInvestors 1
Raised $597.5KInvestors 21
Raised $275KInvestors 4
Raised $550KInvestors 13

Team

6 people
Brian Kim, MDFounder
Medical Advisor & Cofounder

Brian is a board certified ophthalmologist at Harvard Eye Associates who specializes in the clinical treatment of retinal and macular diseases including macular degeneration, diabetic retinopathy, retinal vascular occlusions and other retinal conditions. He received his B.S. in Mechanical Engineering from Columbia University, and after graduation worked as a database programmer for Accenture in the pharmaceutical and biotechnology division. Brian went on to earn his Medical Degree from Pennsylvania State University, and completed a fellowship in Medical Retina at the Bascom Palmer Eye Institute in Florida, and has more than 15 published and presented novel research projects.

Dave WatolaFounder
Chief Technology Officer & Cofounder

Dave began his career at the Caltech/NASA Jet Propulsion Laboratory after earning his BS and MS in Electrical Engineering at Washington State University. There he researched and implemented advanced receivers, statistical pattern recognition systems, machine learning algorithms and error correcting codes for their Communication Systems Research Section. He went on to help co-found Pivotal Technologies, developing IP for the then-emerging Bluetooth and DVI arena, and was later acquired by Broadcom. He continued his startup work at Solarflare Communications, where he was deeply involved in all aspects of the technology. Dave has subsequently been applying image processing, machine learning, and statistical pattern recognition and decision making techniques to numerous cross-disciplinary software solutions.

Jay CormierFounder
CEO & Founder

As an experienced technology executive and entrepreneur, Jay has a strong track record of founding, growing, and turning around businesses. He has completed several successful exits totaling over $750M, across embedded software, SaaS, and hardware solutions. By leveraging his background at Analog Devices, Jay has led marketing, sales, engineering, operations, strategic partnerships, business development, new product strategy and execution. As Vice President & General Manager, Jay achieved exits at Teridian, Sierra Monolithics and Mindspeed using his expertise building high performance, execution-oriented multi-disciplinary teams. Jay earned his BS in Electrical Engineering from Worcester Polytechnic Institute and an MBA from Northeastern University.

Mitul Mehta, MD, MSFounder
Chief Medical Officer & Cofounder

Mitul is a board-certified ophthalmologist with fellowship training in medical and surgical diseases of the retina and practices at UCI’s Gavin Herbert Eye Institute. He earned his Medical Degree from the Keck School of Medicine of USC, and also holds a M.S. in BioPhysics from Georgetown and B.S. from MIT, where he first ventured into software startups. He completed fellowship training in vitreoretinal surgery at the New York Eye & Ear, and conducts research on surgical devices and techniques, as well as on vitreoretinal diseases, such as diabetic retinopathy and macular degeneration. Mitul is the cofounder of the online America Retina Forum and the Young Retina Forum as well as the editor of the retina section for the surgical education website, CSurgeries.com.

Art Reidel
Board Director

Art has helped build and scale profitable businesses in the pharmaceutical software, electronic design automation, and communications industries for more than 40 years. He was CEO of Scintera and co-founder, chairman and CEO of Pharsight Corporation, where he led its IPO. In addition to his management roles, Art is well known in the investment community, and was a venture partner at Lightspeed Venture Partners, a general partner of ABS, and currently a Managing Partner at Horizon Ventures. He has recently served as acting President of WhiteHat Security, Chairman of Eye-Fi and Entelos, and currently is a Director of Materna Medical. Art has been an active member of the Band of Angels since 1995, is a partner in the Band’s Acorn fund and earned a B.S. in Mathematics from MIT.

Jerry Fitch
Board Director

Jerry is an active Advisory Board member of the EvoNexus Incubator, as well as Okami Medical and Inceptus Medical Device Incubator. As President & CEO, he led the spinout of Teridian Semiconductor Corp. in conjunction with private equity firm Golden Gate Capital. He successfully transitioned the turnaround of the company, into the clean tech space which was subsequently sold to Maxim Integrated Products for $315M in cash, a 14x multiple in total invested capital. Prior to joining Teridian, Jerry was the CFO of Airport Group Inc. whose primary investors included The Soros Quantum Fund, GE Capital, and Lockheed Martin. Jerry graduated from the University of Southern California with BS in Business.

Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not required3+ reports filed & assets ≤ $10M

Filed 4 of 6 annual reports (FY2020–FY2025)

653 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form C-ARApr 23, 20240001665160-24-000425
    EDGAR
  • Form C-ARApr 21, 20230001665160-23-000695
    EDGAR
  • Form C-UOct 6, 20220001665160-22-002643
    EDGAR
  • Form C-ARApr 27, 20220001665160-22-000915
    EDGAR
  • Form C-AR/ADec 27, 20210001665160-21-002352
    EDGAR
  • Form C-UOct 15, 20210001665160-21-001813
    EDGAR
  • Form C/ASep 13, 20210001665160-21-001633
    EDGAR
  • Form C/ASep 10, 20210001665160-21-001619
    EDGAR
Source: ManualCIK 0001713933CAShare price $0.80

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.